<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1403">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142891</url>
  </required_header>
  <id_info>
    <org_study_id>8411</org_study_id>
    <nct_id>NCT05142891</nct_id>
  </id_info>
  <brief_title>Renal Tolerance of Amoxicillin and Cloxacillin Combination</brief_title>
  <acronym>Amox-Cloxa</acronym>
  <official_title>Incidence of Actue Kidney Injury in Patients Treated With Amoxicillin and Cloxacillin Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      2015 European Society of Cardiology Guidelines have proposed the combination of Ampicillin&#xD;
      and Cloxacillin for initial empirical treatment of infective endocarditis in acute severely&#xD;
      ill patients (before pathogen identiﬁcation). Yet this combination has never been studied in&#xD;
      clinical trials. High dose penicillin treatments are associated with a risk of&#xD;
      nephrotoxicity.&#xD;
&#xD;
      The investigator's primary purpose is to describe patients treated with high dose Amoxicillin&#xD;
      and Cloxacillin combination and to evaluate its renal tolerance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of patients treated with dual IV therapy combining cloxacillin and amoxicillin in high doses at Strasbourg University Hospital</measure>
    <time_frame>Files analysed retrospectively from January 01, 2016 to December 31, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Endocarditis</condition>
  <condition>Acute Kidney Injury</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient hospitalized at the Strasbourg University Hospital and treated concomitantly&#xD;
        with Amoxicillin IV and Cloxacillin IV for ≥48 hours between January 1, 2016 and December&#xD;
        31, 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patient (≥18 years old)&#xD;
&#xD;
          -  Hospitalized at the Strasbourg University Hospital and treated concomitantly with&#xD;
             Amoxicillin IV and Cloxacillin IV for ≥48 hours between January 1, 2016 and December&#xD;
             31, 2020.&#xD;
&#xD;
          -  Patient not having expressed his opposition, after information, to the reuse of his&#xD;
             data for scientific research purposes.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  Subject under guardianship, curatorship or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yvon RUCH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvon RUCH, MD</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>yvon.ruch@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvon RUCH, MD</last_name>
      <phone>33 3 69 55 12 19</phone>
      <email>yvon.ruch@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Yvon RUCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endocarditis</keyword>
  <keyword>Acute kidney injury</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Cloxacillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

